Skip to main content

Breast Cancer Research and Treatment

Ausgabe 1/2020

Inhalt (24 Artikel)

Review

Impact of NR5A2 and RYR2 3′UTR polymorphisms on the risk of breast cancer in a Chinese Han population

Ying Wei, Xiaolin Wang, Zhe Zhang, Changtao Zhao, Yuwei Chang, Zhiqing Bian, Xinhan Zhao

Open Access Review

A systematic review of communication interventions to help healthcare professionals discuss genetic testing for breast cancer

Rachel Starkings, Valerie Shilling, Valerie Jenkins, Lesley Fallowfield

Open Access Review

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

Michelle D. Hackshaw, Heather E. Danysh, Jasmeet Singh, Mary E. Ritchey, Amy Ladner, Corina Taitt, D. Ross Camidge, Hiroji Iwata, Charles A. Powell

Preclinical study

High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer

Yoshiya Horimoto, Noriko Sasahara, Ritsuko Sasaki, May Thinzar Hlaing, Asumi Sakaguchi, Harumi Saeki, Atsushi Arakawa, Takanori Himuro, Mitsue Saito

Open Access Preclinical study

Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer

Rashmi Verma, Andrew M. Hanby, Kieran Horgan, Eldo T. Verghese, Milene Volpato, Clive R. Carter, Thomas A. Hughes

Preclinical study

Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer

Fang-Ming Chen, Li-Ju Huang, Fu Ou-Yang, Jung-Yu Kan, Li-Chun Kao, Ming-Feng Hou

Preclinical study

CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

Xiaowei Yang, Lu Zhao, Jing Pei, Zhaorui Wang, Jingjie Zhang, Benzhong Wang

Preclinical study

Magnetic resonance imaging and bioimpedance evaluation of lymphatic abnormalities in patients with breast cancer treatment-related lymphedema

Paula M. C. Donahue, Rachelle Crescenzi, Chelsea Lee, Maria Garza, Niral J. Patel, Kalen J. Petersen, Manus J. Donahue

Clinical trial

Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

Ahrong Ham, Min Hwan Kim, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joohyuk Sohn

Clinical trial

Optimal breast reconstruction type for patients treated with neoadjuvant chemotherapy, mastectomy followed by radiation therapy

George E. Naoum, Oluwadamilola T. Oladeru, Andrzej Niemierko, Laura Salama, Jonathan Winograd, Amy Colwell, Waleed O. Arafat, Barbara Smith, Alice Ho, Alphonse G. Taghian

Open Access Clinical trial

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer

Vincent Walter, Chiara Fischer, Thomas M. Deutsch, Catherine Ersing, Juliane Nees, Florian Schütz, Carlo Fremd, Eva-Maria Grischke, Peter Sinn, Sara Y. Brucker, Andreas Schneeweiss, Andreas D. Hartkopf, Markus Wallwiener

Open Access Epidemiology

Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study

Sixten Harborg, Uffe Heide-Jørgensen, Thomas P. Ahern, Marianne Ewertz, Deirdre Cronin-Fenton, Signe Borgquist

Open Access Epidemiology

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score

Stephanie Robertson, Balazs Acs, Michael Lippert, Johan Hartman

Epidemiology

Cardiovascular mortality and morbidity burden in successive and age pre-stratified case–control cohorts of breast cancer women. A population-based study

Lidia Staszewsky, Fabio Robusto, Vito Lepore, Lucia Bisceglia, Vito Petrarolo, Antonio D’Ettorre, Gianni Tognoni, Roberto Latini

Epidemiology

Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management

Marianna Cavazza, Helen Banks, Michele Ercolanoni, Gjiliola Cukaj, Giulia Bianchi, Giuseppe Capri, Francesco Longo

Epidemiology

Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data

Melissa K. Accordino, Jason D. Wright, Donna Buono, Aijing Lin, Yongmei Huang, Alfred I. Neugut, Grace C. Hillyer, Dawn L. Hershman

Epidemiology

Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative

Dan Guo, Michael Hendryx, Xiaoyun Liang, JoAnn E. Manson, Ka He, Mara Z. Vitolins, Yueyao Li, Juhua Luo

Epidemiology

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Diana G. Wang, Dulce M. Barrios, Victoria S. Blinder, Jacqueline F. Bromberg, Pamela R. Drullinsky, Samuel A. Funt, Komal L. Jhaveri, Diana E. Lake, Tomas Lyons, Shanu Modi, Pedram Razavi, Michelle Sidel, Tiffany A. Traina, Linda T. Vahdat, Mario E. Lacouture

Letter to the Editor

Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer

Marta Perachino, Francesca Poggio, Matteo Lambertini

Letter to the Editor

A case for Tamoxifen with ovarian function suppression

Pallavi Kopparthy, Karen Daily

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.